The NICE has specifically recommended a triplet therapy comprised of Kyprolis (carfilzomib), lenalidomide and dexamethasone in order to treat previously treated patients with multiple myeloma.
On behalf of final guidance, National Institute for Health and Care Excellence backed the use of triplet combination Kyprolis, lenalidomide and dexamethasone for patients with MM, who have had at least a single previous therapy, including bortezomib (targeted therapy).
In the carried out clinical trials of the triplet, Kyprolis plus lenalidomide and dexamethasone has demonstrated extend periods of remission and help patients in order to live longer, in comparison to the current second-line therapy for multiple myeloma patients, lenalidomide and dexamethasone alone.
According to the National Institute for Health and Care Excellence, “The independent appraisal committee saw findings that reveal the advantages of the triple combination therapy demonstrated to carry on with for up to the 6-years.”
After its review, the committee stated the most-likely cost-effectiveness estimates for this triplet (Kyprolis, lenalidomide and dexamethasone) are within what National Institute for Health and Care Excellence considers a cost-effective use of the National Health Service resources.
According to a statement by Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Assessment at NICE, “The recommendation of our committee will be welcomed by patients with MM who have told us of the requirement of a new second line treatment option that can offer longer periods of the remission as well as improves the survival.”
“The clinical findings demonstrate that the benefits of this triplet continue following the treatment has stopped. A positive decision has been made possible following the company and National Health Service England came to a commercial arrangement which enables the carfilzomib to be used on the National Health Service with a confidential discount,” Meindert Boysen added.